Fundraising Fox
InnovoTEX
Austin, US · Founded 2022 · Delaware corporation
Find your way into InnovoTEX
Sign up to see every warm intro you have to InnovoTEX
- Paths you didn't know you had: your email and LinkedIn already hold routes to the InnovoTEX team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Innovotex develops macrocycle-mediated targeted delivery systems for cancer therapies, building multi-modal platforms intended to improve the effectiveness of targeted cancer treatments. The company operates in oncology-focused therapeutics.
Founders & leadership
InnovoTEX was founded in 2022 by Jonathan Arambula.
JA
Jonathan ArambulaExecutive Chairman and Co-FounderJonathan Arambula is Executive Chairman and Co-Founder of INNOVOTEX, a cancer therapeutics company developing targeted delivery systems for oncology. He previously held VP Research and CEO roles at other biotech companies, served as a biochemistry professor and American Cancer Society Postdoctoral Fellow at UT Austin and MD Anderson Cancer Center, and has contributed to peer-reviewed publications and patents in cancer drug discovery and translational development.
JS
Jonathan SesslerNamed on SEC filing
KK
Krystle KarosikNamed on SEC filing
JA
Joseph ArambulaNamed on SEC filing
KK
Krystle KaroscikNamed on SEC filing
JH
James HusseyNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$3.6M disclosed across 3 rounds · 2023–2026
▶$2.7MraisedAug 2026 · 21 investors · BiotechnologyRule 506(b)
▶$2.7MraisedAug 2026 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krystle KaroscikExecutive Officer, Director
- Jonathan ArambulaDirector
- Jonathan SesslerDirector
- James HusseyDirector
- Offering amount
- $4M
- Amount sold
- $2.7M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$75KraisedAug 2026 · 2 investors · BiotechnologyRule 506(b)
▶$75KraisedAug 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krystle KaroscikExecutive Officer, Director
- Jonathan ArambulaDirector
- Jonathan SesslerDirector
- James HusseyDirector
- Offering amount
- $75K
- Amount sold
- $75K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$829.8KraisedMar 2023 · 8 investors · Other Health CareRule 506(b)
▶$829.8KraisedMar 2023 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SesslerDirector
- Krystle KarosikExecutive Officer
- Joseph ArambulaExecutive Officer, Director
- Offering amount
- $829.8K
- Amount sold
- $829.8K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
NuvectisNuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma. Its drug candidates are in early-stage clinical trials for patients with advanced solid tumors.
Renovo RxRenovoRx is a life sciences company developing targeted drug delivery for cancer treatment, including its TAMP therapy approach. It operates as a publicly listed biopharmaceutical/medical device company focused on oncology.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies working in the same space as InnovoTEX.
Frequently asked questions
- What does InnovoTEX do?
- Innovotex develops macrocycle-mediated targeted delivery systems for cancer therapies, building multi-modal platforms intended to improve the effectiveness of targeted cancer treatments. The company operates in oncology-focused therapeutics.
- Who founded InnovoTEX?
- InnovoTEX was founded by Jonathan Arambula in 2022.
- How much funding has InnovoTEX raised?
- InnovoTEX has disclosed $3.6M raised across 3 rounds.
- Where is InnovoTEX headquartered?
- InnovoTEX is headquartered in Austin, US.